Development of a Human Anti-MUC1 Antibody for Breast Cancer Treatment
Author Information
Author(s): Thie Holger, Toleikis Lars, Li Jiandong, von Wasielewski Reinhard, Bastert Gunther, Schirrmann Thomas, Esteves Isabel Tourais, Behrens Christian K., Fournes Bénédict, Fournier Nathalie, de Romeuf Christophe, Hust Michael, Dübel Stefan
Primary Institution: Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Braunschweig, Germany
Hypothesis
Can a human anti-MUC1 scFv antibody be effectively generated and tested for therapeutic use in breast cancer?
Conclusion
The study successfully generated a highly specific anti-MUC1 antibody, but its therapeutic efficacy was limited by the target biology.
Supporting Evidence
- The anti-MUC1 scFv reacted with tumor cells in over 80% of breast cancer tissue samples.
- The affinity of the scFv was increased up to 500-fold through mutagenesis and phage display.
- The antibody showed low reactivity with non-tumor tissues.
- Despite high specificity, the therapeutic success was limited by the target biology.
Takeaway
Scientists created a special antibody to fight breast cancer, but it didn't work as well as they hoped because of how the cancer cells behave.
Methodology
The study involved isolating a human scFv antibody from breast cancer patients, followed by affinity maturation and testing in vitro and in vivo.
Limitations
The antibody showed low stability and affinity, which limited its effectiveness in therapeutic applications.
Participant Demographics
Breast cancer patients who were vaccinated with MUC1 glycopeptides.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website